🔎 Trials Near Me

Home › Burkitt Lymphoma › Alabama

Burkitt Lymphoma clinical trials in Alabama

7 studies for Burkitt Lymphoma are looking for participants at sites in Alabama.

Cities in Alabama

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Hospital of Alabama, Birmingham
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Sep 28, 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Children's Hospital of Alabama, Birmingham
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Hospital of Alabama, Birmingham
  • USA Health Strada Patient Care Center, Mobile
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Children's Hospital of Alabama, Birmingham
  • USA Health Strada Patient Care Center, Mobile
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • University of Alabama at Birmingham, Birmingham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT04260022

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • Children's of Alabama/University of Alabama in Birmingham(UAB), Birmingham
RecruitingPhase 2
Ages 1 to 25 · All sexes · Updated May 4, 2025 · NCT03509961

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

  • University of Alabama at Birmingham, Birmingham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.